Sbir phase I- topic 410 - cancer clinical trials recruitment and retention tools for participant engagement.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91020C00017
- Awardee
-
Melax Technologies Inc. UEI ME3MA61LJD79
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $400,000
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · PHS20201 · Posted Jun 21, 2019
- Contract value 100% obligated
- $400,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 15 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $400,000 |
About this award
This $400,000 firm fixed price contract was awarded by the National Institutes of Health National Cancer Institute to Melax Technologies Inc., doing business as Private, for SBIR Phase I research titled "Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement." The solicitation sought proposals to support NIH and CDC agency missions through research topics including cancer imaging tools, clinical trials tools, and cancer informatics software. The University of Texas Health Science Center at Houston was awarded a subcontract under the prime to develop and evaluate an extension to an engagement tool for consumers and conduct usability testing. Place of performance will be in Houston, Texas. The contract has a total small business set-aside designation and runs from September 2020 to September 2021.
Quick answers
Who was awarded contract 75N91020C00017?
75N91020C00017 was awarded to Melax Technologies Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2020.
How much is contract 75N91020C00017 worth?
The government has obligated $400,000 on 75N91020C00017.
Was contract 75N91020C00017 competed?
The extent of competition for 75N91020C00017 was full and open competition after exclusion of sources. The government received 15 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award